Alleviation of rheumatoid arthritis by cell-transducible methotrexate upon transcutaneous delivery

Biomaterials

Volumn 33, Issue 5, 2012, Pages 1563-1572

  Lee, Sang Won ^a   Kim, Ji Hye ^a   Park, Min Chan ^a   Park, Yong Beom ^a   Chae, Wook Jin ^b   Morio, Tomohiro ^c   Lee, Dong Ho ^d   Yang, Sang Hwa ^e   Lee, Seung Kyou ^d   Lee, Soo Kon ^a   Lee, Sang Kyou ^d,e  

^a Yonsei University College of Medicine   (South Korea)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d ForHumanTech Co Ltd   (South Korea)

^e Yonsei University   (South Korea)

Author keywords

Arthritis; Cytotoxicity; Drug delivery; Immunomodulation; Inflammation

Indexed keywords

ARTHRITIS; AUTOIMMUNE DISEASE; BIOLOGICAL AGENTS; COLLAGEN-INDUCED ARTHRITIS; CYTOKINES; EX-VIVO; IMMUNOMODULATION; IN-VIVO; INFLAMMATION; INFLAMMATORY CYTOKINES; MICROCOMPUTED TOMOGRAPHY; ORAL ADMINISTRATION; RHEUMATOID ARTHRITIS; THERAPEUTIC EFFICACY; THERAPEUTIC MODALITY; THERAPEUTIC POTENTIALS; TRANSCUTANEOUS; TRANSCUTANEOUS DELIVERY; TUMOR NECROSIS FACTORS;

COMPUTERIZED TOMOGRAPHY; CYTOTOXICITY; DRUG DELIVERY; HEALTH; MAMMALS; THREE DIMENSIONAL; TOMOGRAPHY;

JOINTS (ANATOMY);

CYTOKINE; ETANERCEPT; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG PENETRATION; JOINT; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; THREE DIMENSIONAL IMAGING;

ADMINISTRATION, CUTANEOUS; ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL DEATH; CELL MEMBRANE PERMEABILITY; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; IMMUNOGLOBULIN G; INFLAMMATION MEDIATORS; KINETICS; MALE; METHOTREXATE; MICE; RECEPTORS, TUMOR NECROSIS FACTOR; TETRAHYDROFOLATE DEHYDROGENASE; TISSUE DISTRIBUTION; TREATMENT OUTCOME; X-RAY MICROTOMOGRAPHY;

MUS;

EID: 83355177996     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.10.079     Document Type: Article

References (33)

1. Choy E.H., Panayi G.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344:907-916.
2. Feldmann M., Brennan F.M., Maini R.N. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996, 14:397-440.
3. Zwerina J., Redlich K., Schett G., Smolen J.S. Pathogenesis of rheumatoid arthritis: targeting cytokines. Ann N Y Acad Sci 2005, 1051:716-729.
4. Paulus H.E. The use of combinations of disease-modifying antirheumatic agents in rheumatoid arthritis. Arthritis Rheum 1990, 33:113-120.
5. Weinblatt M.E., Kaplan H., Germain B.F., Merriman R.C., Solomon S.D., Wall B., et al. Methotrexate in rheumatoid arthritis: effects on disease activity in a multicenter prospective study. J Rheumatol 1991, 18:334-338.
6. Weinblatt M.E., Weissman B.N., Holdsworth D.E., Fraser P.A., Maier A.L., Falchuk K.R., et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. Arthritis Rheum 1992, 35:129-137.
7. van Riel P.L., van der Heijde D.M., Nuver-Zwart I.H., van de Putte L.B. Radiographic progression in rheumatoid arthritis: results of 3 comparative trials. J Rheumatol 1995, 22:1797-1799.
8. Mello S.B., Barros D.M., Silva A.S., Laurindo I.M., Novaes G.S. Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis. Rheumatology 2000, 39:533-536.
9. Perkins D.J., St Clair E.W., Misukonis M.A., Weinberg J.B. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). Arthritis Rheum 1998, 41:2205-2210.
10. Schnabel A., Gross W.L. Low-dose methotrexate in rheumatic diseases-efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 1994, 23:310-327.
11. Kremer J.M., Alarcón G.S., Lightfoot R.W., Willkens R.F., Furst D.E., Williams H.J., et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994, 37:316-328.
12. van Ede A.E., Laan R.F., Blom H.J., De Abreu R.A., van de Putte L.B. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998, 27:277-292.
13. Scott D.L., Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006, 355:704-712.
14. Silverman G.J., Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003, 48:1484-1492.
15. Curtis J.R., Xi J., Patkar N., Xie A., Saag K.G., Martin C. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum 2007, 56:4226-4227.
16. Kavanaugh A.F. B cell targeted therapies: safety considerations. J Rheumatol 2006, (Suppl 77):18-23.
17. Sfikakis P.P. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010, 11:180-210.
18. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., Stapel S., Lems W.F., Aarden L., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66:921-926.
19. Radstake T.R., Svenson M., Eijsbouts A.M., van den Hoogen F.H., Enevold C., van Riel P.L., et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1739-1745.
20. Schreiber S., Mahmoud A., Vuia A., Rübbelke M.K., Schmidt E., Schaller M., et al. Reconstructed epidermis versus human and animal skin in skin absorption studies. Toxicol in Vitro 2005, 19:813-822.
21. Lee S.W., Kim J.H., Park Y.B., Lee S.K. Bortezomib attenuates murine collagen-induced arthritis. Ann Rheum Dis 2009, 68:1761-1767.
22. Shen T., Zhu Q.X., Yang S., Wu C.H., Zhang H.F., Zhou C.F., et al. Trichloroethylene induced cutaneous irritation in BALB/c hairless mice: histopathological changes and oxidative damage. Toxicology 2008, 248:113.
23. Parfitt A.M., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987, 2:595-610.
24. Delgado M., Abad C., Martinez C., Leceta J., Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001, 7:563-568.
25. Gonzalez-Rey E., Fernandez-Martin A., Chorny A., Delgado M. Vasoactive intestinal peptide induces CD4+, CD25+ T regulatory cells with therapeutic effect in collagen- induced arthritis. Arthritis Rheum 2006, 54:864-876.
26. Chatterjee D.J., Li W.Y., Koda R.T. Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. Pharm Res 1997, 14:1058-1065.
27. Wong T.W., Zhao Y.L., Sen A., Hui S.W. Pilot study of topical delivery of methotrexate by electroporation. Br J Dermatol 2005, 152:524-530.
28. Back K.H., Lee W.P., Diehl L.J., Ross J., Gribling P., Zhang Y., et al. Quantification of cortical bone loss and repair for therapeutic evaluation in collagen-induced arthritis, by micro-computed tomography and automated image analysis. Arthritis Rheum 2004, 50:3377-3386.
29. Botter S.M., van Osch G.J., Waarsing J.H., Day J.S., Verhaar J.A., Pols H.A., et al. Quantification of subchondral bone changes in a murine osteoarthritis model using micro-CT. Biorheology 2006, 43:379-388.
30. Swieszkowski W., Tuan B.H., Kurzydlowski K.J., Hutmacher D.W. Repair and regeneration of osteochondral defects in the articular joints. Biomol Eng 2007, 24:489-495.
31. Goldring S.R., Gravallese E.M. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2000, 12:195-199.
32. Chabner B.A., Allegra C.J., Curt G.A., Clendeninn N.J., Baram J., Koizumi S., et al. Polyglutamation of methotrexate. Is methotrexate a prodrug?. J Clin Invest 1985, 76:907-912.
33. Fry D.W., Anderson L.A., Borst M., Goldman I.D. Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Res 1983, 43:1087-1092.